959121-99-4

Basic information

• Product Name: 3-BROMO-7-METHOXYQUINOLINE
• Synonyms: 3-BROMO-7-METHOXYQUINOLINE
• CAS NO: 959121-99-4
• Molecular Formula: C₁₀H₈BrNO
• Molecular Weight: 238.083
• Mol File: 959121-99-4.mol

Chemical Properties

• Boiling Point: 318.3 °C at 760 mmHg
• Flash Point: 146.3 °C
• Appearance: /
• Density: 1.516 g/cm³
• Vapor Pressure: 0.000681mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: 2-8°C
• PKA: 2.85±0.25(Predicted)
• CAS DataBase Reference: 3-BROMO-7-METHOXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-7-METHOXYQUINOLINE(959121-99-4)
• EPA Substance Registry System: 3-BROMO-7-METHOXYQUINOLINE(959121-99-4)

Safety Data

• Hazardous Substances Data: 959121-99-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-7-methoxyquinoline is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for the creation of novel compounds with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-7-methoxyquinoline serves as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness in controlling pests and weeds, thereby improving crop yields and quality.
Used in Heterocyclic Compounds Production:
3-Bromo-7-methoxyquinoline is utilized as a building block in the synthesis of heterocyclic compounds, which are important in various fields, including organic chemistry, materials science, and medicinal chemistry. Its presence in these compounds can impart unique properties and functionalities, expanding their applications in different industries.
Used in Research and Development:
3-Bromo-7-methoxyquinoline is employed in research and development for exploring its potential therapeutic applications. Its diverse biological activities make it a promising candidate for the development of new treatments for various diseases and conditions. Ongoing studies aim to uncover its full potential and optimize its use in medical and pharmaceutical settings.

InChI:InChI=1/C10H8BrNO/c1-13-9-3-2-7-4-8(11)6-12-10(7)5-9/h2-6H,1H3

Upstream product

• 124-41-4 sodium methylate 
• 30450-62-5 7-nitro-1,2,3,4-tetrahydro-quinoline 
• 4964-76-5 7-methoxyquinoline 
• 2065-75-0 2-Bromo-malonaldehyde 
• 536-90-3 m-Anisidine 

Downstream Products

• 1017860-10-4 7-methoxy-3-(3-methoxyphenyl)quinoline 
• 1383379-65-4 4-(7-hydroxyquinolin-3-yl)benzoic acid 
• 1383379-86-9 4-(7-methoxyquinolin-3-yl)benzoic acid 

Relevant articles and documents

Synthetic method of 3-bromo-7-methoxyl quinoline

The invention provides a synthetic method of 3-bromo-7-methoxyl quinoline. The synthetic method of 3-bromo-7-methoxyl quinoline comprises the following steps: 1) adding a solvent into 7-nitryl-1,2,3,4-tetrahydroquinoline, adding DDQ and stirring the mixture to react to obtain 7-nitryl quinoline, wherein the molar ratio of 7-nitryl-1,2,3,4-tetrahydroquinoline and DDQ is 1: (1-5); 2) adding the solvent into 7-nitryl quinoline, heating the mixture, adding N-bromo-succinimide to react to obtain 3-bromo-7-nitryl quinoline in an insulating manner; and 3) dissolving 3-bromo-7-nitryl quinoline in thesolvent, adding sodium methylate, and heating the mixture to stir and react to obtain 3-bromo-7-methoxyl quinoline. The synthetic method of 3-bromo-7-methoxyl quinoline is concise in synthetic route,reasonable in process selection, low in raw material cost, simple and easy, convenient to operate and post-treat, high in total yield and easy to amplify.

Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains

A series of quinoylalkyl side chains was designed and synthesized, followed by introduction into ketolides by coupling with building block 6 or 32. The corresponding targets 7a–n, 33b, and 33e were tested for their in vitro activities against a series of macrolide-sensitive and macrolide-resistant pathogens. Some of them showed a similar antibacterial spectrum and comparable activity to telithromycin. Among them, two C2-F ketolides, compounds 33b and 33e, displayed excellent activities against macrolide-sensitive and macrolide-resistant pathogens.

NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES

The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases.The invention further relates to suitable inhibitors and to a method for the production thereof.

Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: Potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases

Human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the reduction of the weak estrogen estrone (E1) to the highly potent estradiol (E2). This reaction takes place in the target cell where the estrogenic effect is exerted via the estrogen receptor (ER). Estrogens, especially E2, are known to stimulate the proliferation of hormone-dependent diseases. 17β-HSD1 is overexpressed in many breast tumors. Thus, it is an attractive target for the treatment of these diseases. Ligand- and structure-based drug design led to the discovery of novel, selective, and potent inhibitors of 17β-HSD1. Phenyl-substituted bicyclic moieties were synthesized as mimics of the steroidal substrate. Computational methods were used to obtain insight into their interactions with the protein. Compound 5 turned out to be a highly potent inhibitor of 17β-HSD1 showing good selectivity (17β-HSD2, ERα and β), medium cell permeation, reasonable metabolic stability (rat hepatic microsomes), and little inhibition of hepatic CYP enzymes.